Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage

NCT01783717 · Unknown status

Last updated 2026-05-28

This clinical trial tests whether the medication exenatide can help reduce body weight in adults who have obesity and/or diabetes caused by damage to the hypothalamus.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 10 people Planned (estimated).

Who can join Ages 18–55 · all sexes

Timeline Started 2012-12 · est. completion 2015-07

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT01783717 ↗

Description as written by the study sponsor.

The purpose of this study is to examine the effect of exenatide on body weight and glycemic control in subjects with obesity and/or diabetes mellitus due to hypothalamic damage.

Treatments tested

Exenatide also known as Byetta Drug

5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks

Main thing measured	Change in body weight frome baseline to end of the study.
Sponsor	Huashan Hospital
Conditions studied	Hypothalamic Obesity, Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01783717 ↗